Comparative Efficacy and Safety of De-escalation, Abbreviation, and Standard Potent P2Y12 Inhibitor–Based Dual Antiplatelet Therapy Strategies After Acute Coronary Syndrome: A Network Meta-Analysis

Clicks: 10
ID: 332327
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #71 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Potent P2Y12 inhibitor–based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain. Methods Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (1) short-term potent P2Y12 inhibitor–based DAPT de-escalation to clopidogrel-based DAPT, (2) Abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy, and (3) standard 12-month potent P2Y12 inhibitor–based DAPT. Primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. Primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Results Seven randomized controlled trials involving 20,673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, p=0.002; and RR 0.43, 95% CI 0.33-0.58, p<0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, p<0.001; and RR 0.72, 95% CI 0.61-0.84, p<0.001, respectively) without increasing MACE or other ischemic outcomes. Indirect comparison indicated that de-escalation vs abbreviation strategies demonstrated comparable MACE, NACE and bleeding outcomes. Conclusions Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy effectively reduce bleeding risk without compromising ischemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.
Reference Key
openalex_W7221749660 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yee-Jen Wu, Hungju Lin, Yi-Chen Chou, Yen‐Hung Lin, Chi‐Sheng Hung
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag173
URL
https://doi.org/10.1093/ehjopen/oeag173
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.